The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators

Volume 323:1505-1511		November 29, 1990		Number 22

The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators

Add to Personal Archive

Add to Citation Manager

Notify a Friend

E-mail When Cited

PubMed Citation

Abstract

BACKGROUND. Nonrheumatic atrial fibrillation increases the risk of stroke, presumably from atrial thromboemboli. There is uncertainty about the efficacy and risks of long-term warfarin therapy to prevent stroke. METHODS. We conducted an unblinded, randomized, controlled trial of long-term, low-dose warfarin therapy (target prothrombin-time ratio, 1.2 to 1.5) in patients with nonrheumatic atrial fibrillation. The control group was not given warfarin but could choose to take aspirin. RESULTS. A total of 420 patients entered the trial (212 in the warfarin group and 208 in the control group) and were followed for an average of 2.2 years. Prothrombin times in the warfarin group were in the target range 83 percent of the time. Only 10 percent of the patients assigned to receive warfarin discontinued the drug permanently. There were 2 strokes in the warfarin group (incidence, 0.41 percent per year) as compared with 13 strokes in the control group (incidence, 2.98 percent per year), for a reduction of 86 percent in the risk of stroke (warfarin:control incidence ratio = 0.14; 95 percent confidence interval, 0.04 to 0.49; P = 0.0022). There were 37 deaths altogether. The death rate was markedly lower in the warfarin group than in the control group: 2.25 percent as compared with 5.97 percent per year, for an incidence ratio of 0.38 (95 percent confidence interval, 0.17 to 0.82; P = 0.005). There was one fatal hemorrhage in each group. The frequency of bleeding events that led to hospitalization or transfusion was essentially the same in both groups. The warfarin group had a higher rate of minor hemorrhage than the control group (38 vs. 21 patients). CONCLUSIONS. Long-term low-dose warfarin therapy is highly effective in preventing stroke in patients with non-rheumatic atrial fibrillation, and can be quite safe with careful monitoring.

This article has been cited by other articles:

Holmes, D. R. Jr, Schwartz, R. S. (2009). Left Atrial Appendage Occlusion Eliminates the Need for Warfarin. Circulation 120: 1919-1926 [Full Text]
Chan, K. E., Lazarus, J. M., Thadhani, R., Hakim, R. M. (2009). Warfarin Use Associates with Increased Risk for Stroke in Hemodialysis Patients with Atrial Fibrillation. J. Am. Soc. Nephrol. 20: 2223-2233 [Abstract] [Full Text]
Ezekowitz, M. D., Koti, M. J., Fulton, B. (2009). Reducing Stroke Rates in Patients With Atrial Fibrillation: How Low Can We Go?. Circulation 120: 1169-1170 [Full Text]
Ellis, D. J., Usman, M. H., Milner, P. G., Canafax, D. M., Ezekowitz, M. D. (2009). The First Evaluation of a Novel Vitamin K Antagonist, Tecarfarin (ATI-5923), in Patients With Atrial Fibrillation. Circulation 120: 1029-1035 [Abstract] [Full Text]
Crandall, M. A., Bradley, D. J., Packer, D. L., Asirvatham, S. J. (2009). Contemporary Management of Atrial Fibrillation: Update on Anticoagulation and Invasive Management Strategies. Mayo Clin Proc. 84: 643-662 [Abstract] [Full Text]
van Walraven, C., Hart, R. G., Connolly, S., Austin, P. C., Mant, J., Hobbs, F.D. R., Koudstaal, P. J., Petersen, P., Perez-Gomez, F., Knottnerus, J. A., Boode, B., Ezekowitz, M. D., Singer, D. E. (2009). Effect of Age on Stroke Prevention Therapy in Patients With Atrial Fibrillation: The Atrial Fibrillation Investigators. Stroke 40: 1410-1416 [Abstract] [Full Text]
Andersen, L V, Vestergaard, P, Deichgraeber, P, Lindholt, J S, Mortensen, L S, Frost, L (2008). Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis. Heart 94: 1607-1613 [Abstract] [Full Text]
Nagarajarao, H. S., Penman, A. D., Taylor, H. A., Mosley, T. H., Butler, K., Skelton, T. N., Samdarshi, T. E., Aru, G., Fox, E. R. (2008). The Predictive Value of Left Atrial Size for Incident Ischemic Stroke and All-Cause Mortality in African Americans: The Atherosclerosis Risk in Communities (ARIC) Study. Stroke 39: 2701-2706 [Abstract] [Full Text]
Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M., Palareti, G. (2008). Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 160S-198S [Abstract] [Full Text]
Patrono, C., Baigent, C., Hirsh, J., Roth, G. (2008). Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 199S-233S [Abstract] [Full Text]
Schulman, S., Beyth, R. J., Kearon, C., Levine, M. N. (2008). Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 257S-298S [Abstract] [Full Text]
Singer, D. E., Albers, G. W., Dalen, J. E., Fang, M. C., Go, A. S., Halperin, J. L., Lip, G. Y. H., Manning, W. J. (2008). Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 546S-592S [Abstract] [Full Text]
Salem, D. N., O'Gara, P. T., Madias, C., Pauker, S. G. (2008). Valvular and Structural Heart Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 593S-629S [Abstract] [Full Text]
Levi, M., Hovingh, G. K., Cannegieter, S. C., Vermeulen, M., Buller, H. R., Rosendaal, F. R. (2008). Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood 111: 4471-4476 [Abstract] [Full Text]
Nieuwlaat, R., Dinh, T., Olsson, S. B., Camm, A. J., Capucci, A., Tieleman, R. G., Lip, G. Y.H., Crijns, H. J.G.M., on behalf of the Euro Heart Survey Investigators, (2008). Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation?. Eur Heart J 29: 915-922 [Abstract] [Full Text]
Hansen, M. L., Gadsboll, N., Gislason, G. H., Abildstrom, S. Z., Schramm, T. K., Folke, F., Friberg, J., Sorensen, R., Rasmussen, S., Poulsen, H. E., Kober, L., Madsen, M., Torp-Pedersen, C. (2008). Atrial fibrillation pharmacotherapy after hospital discharge between 1995 and 2004: a shift towards beta-blockers. Europace 10: 395-402 [Abstract] [Full Text]
Garwood, C. L, Corbett, T. L (2008). Use of Anticoagulation in Elderly Patients with Atrial Fibrillation Who Are at Risk for Falls. The Annals of Pharmacotherapy 42: 523-532 [Abstract] [Full Text]
Hohnloser, S. H., Pajitnev, D., Pogue, J., Healey, J. S., Pfeffer, M. A., Yusuf, S., Connolly, S. J., for the ACTIVE W Investigators, (2007). Incidence of Stroke in Paroxysmal Versus Sustained Atrial Fibrillation in Patients Taking Oral Anticoagulation or Combined Antiplatelet Therapy: An ACTIVE W Substudy. J Am Coll Cardiol 50: 2156-2161 [Abstract] [Full Text]
Kirchhof, P., Auricchio, A., Bax, J., Crijns, H., Camm, J., Diener, H.-C., Goette, A., Hindricks, G., Hohnloser, S., Kappenberger, L., Kuck, K.-H., Lip, G. Y.H., Olsson, B., Meinertz, T., Priori, S., Ravens, U., Steinbeck, G., Svernhage, E., Tijssen, J., Vincent, A., Breithardt, G. (2007). Outcome parameters for trials in atrial fibrillation: executive summary: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eur Heart J 28: 2803-2817 [Abstract] [Full Text]
Nutescu, E. A. (2007). ASHP Therapeutic Position Statement on Antithrombotic Therapy in Chronic Atrial Fibrillation. Am J Health Syst Pharm 64: 2281-2291 [Full Text]
Khella, S., Bleicher, M. B. (2007). Stroke and Its Prevention in Chronic Kidney Disease. CJASN 2: 1343-1351 [Abstract] [Full Text]
Kirchhof, P., Auricchio, A., Bax, J., Crijns, H., Camm, J., Diener, H.-C., Goette, A., Hindricks, G., Hohnloser, S., Kappenberger, L., Kuck, K.-H., Lip, G. Y.H., Olsson, B., Meinertz, T., Priori, S., Ravens, U., Steinbeck, G., Svernhage, E., Tijssen, J., Vincent, A., Breithardt, G. (2007). Outcome parameters for trials in atrial fibrillation: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace 9: 1006-1023 [Abstract] [Full Text]
Liao, J., Khalid, Z., Scallan, C., Morillo, C., O'Donnell, M. (2007). Noninvasive Cardiac Monitoring for Detecting Paroxysmal Atrial Fibrillation or Flutter After Acute Ischemic Stroke: A Systematic Review. Stroke 38: 2935-2940 [Abstract] [Full Text]
Connolly, S. J., Eikelboom, J., O'Donnell, M., Pogue, J., Yusuf, S. (2007). Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation. Circulation 116: 449-455 [Full Text]
Siu, C.-W., Jim, M.-H., Ho, H.-H., Miu, R., Lee, S. W.L., Lau, C.-P., Tse, H.-F. (2007). Transient Atrial Fibrillation Complicating Acute Inferior Myocardial Infarction: Implications for Future Risk of Ischemic Stroke. Chest 132: 44-49 [Abstract] [Full Text]
Hart, R. G., Pearce, L. A., Aguilar, M. I. (2007). Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation. ANN INTERN MED 146: 857-867 [Abstract] [Full Text]
Authors/Task Force Members, , Ryden, L., Standl, E., Bartnik, M., Berghe, G. V. d., Betteridge, J., de Boer, M.-J., Cosentino, F., Jonsson, B., Laakso, M., Malmberg, K., Priori, S., Ostergren, J., Tuomilehto, J., Thrainsdottir, I., Other Contributors, , Vanhorebeek, I., Stramba-Badiale, M., Lindgren, P., Qiao, Q., ESC Committee for Practice Guidelines (CPG), , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, J., Dean, V., Deckers, J., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J., Zamorano, J. L., Document Reviewers, , Deckers, J. W., Bertrand, M., Charbonnel, B., Erdmann, E., Ferrannini, E., Flyvbjerg, A., Gohlke, H., Juanatey, J. R. G., Graham, I., Monteiro, P. F., Parhofer, K., Pyorala, K., Raz, I., Schernthaner, G., Volpe, M., Wood, D. (2007). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J Suppl 9: C3-C74 [Full Text]
Holbrook, A., Labiris, R., Goldsmith, C. H., Ota, K., Harb, S., Sebaldt, R. J. (2007). Influence of decision aids on patient preferences for anticoagulant therapy: a randomized trial. CMAJ 176: 1583-1587 [Abstract] [Full Text]
Perez-Gomez, F., Iriarte, J. A., Zumalde, J., Berjon, J., Salvador, A., Alegria, E., Maluenda, M. P., Asenjo, S., Perez-Saldana, R., de la Torre, R. G., Bover, R., Fernandez, C. (2007). Antithrombotic therapy in elderly patients with atrial fibrillation: effects and bleeding complications: a stratified analysis of the NASPEAF randomized trial. Eur Heart J 28: 996-1003 [Abstract] [Full Text]
Rash, A., Downes, T., Portner, R., Yeo, W. W., Morgan, N., Channer, K. S. (2007). A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing 36: 151-156 [Abstract] [Full Text]
Glazer, N. L., Dublin, S., Smith, N. L., French, B., Jackson, L. A., Hrachovec, J. B., Siscovick, D. S., Psaty, B. M., Heckbert, S. R. (2007). Newly Detected Atrial Fibrillation and Compliance With Antithrombotic Guidelines. Arch Intern Med 167: 246-252 [Abstract] [Full Text]
Flaherty, M. L., Kissela, B., Woo, D., Kleindorfer, D., Alwell, K., Sekar, P., Moomaw, C. J., Haverbusch, M., Broderick, J. P. (2007). The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology 68: 116-121 [Abstract] [Full Text]
Authors/Task Force Members, , Ryden, L., Standl, E., Bartnik, M., Van den Berghe, G., Betteridge, J., de Boer, M.-J., Cosentino, F., Jonsson, B., Laakso, M., Malmberg, K., Priori, S., Ostergren, J., Tuomilehto, J., Thrainsdottir, I., Other Contributors, , Vanhorebeek, I., Stramba-Badiale, M., Lindgren, P., Qiao, Q., ESC Committee for Practice Guidelines (CPG), , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, J., Dean, V., Deckers, J., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J., Zamorano, J. L., Document Reviewers, , Deckers, J. W., Bertrand, M., Charbonnel, B., Erdmann, E., Ferrannini, E., Flyvbjerg, A., Gohlke, H., Juanatey, J. R. G., Graham, I., Monteiro, P. F., Parhofer, K., Pyorala, K., Raz, I., Schernthaner, G., Volpe, M., Wood, D. (2007). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28: 88-136 [Full Text]
Jolobe, O. M. (2006). Stroke prophylaxis in atrial fibrillation. Eur Heart J 27: 2370-2370 [Full Text]
Monte, S., Macchia, A., Pellegrini, F., Romero, M., Lepore, V., D'Ettorre, A., Saugo, M., Tavazzi, L., Tognoni, G. (2006). Antithrombotic treatment is strongly underused despite reducing overall mortality among high-risk elderly patients hospitalized with atrial fibrillation. Eur Heart J 27: 2217-2223 [Abstract] [Full Text]
Writing Committee Members, , Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., Olsson, S. B., Prystowsky, E. N., Tamargo, J. L., Wann, S., ACC/AHA Task Force Members, , Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B., ESC Committee for Practice Guidelines, , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, A. J., Dean, V., Deckers, J. W., Despres, C., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J. L., Zamorano, J. L. (2006). ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 8: 651-745 [Full Text]
Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., Olsson, S. B., Prystowsky, E. N., Tamargo, J. L., Wann, S. (2006). ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society . J Am Coll Cardiol 48: 854-906 [Full Text]
Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., Olsson, S. B., Prystowsky, E. N., Tamargo, J. L., Wann, S. (2006). ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society . J Am Coll Cardiol 48: e149-e246 [Full Text]
Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., Olsson, S. B., Prystowsky, E. N., Tamargo, J. L., Wann, S., ACC/AHA TASK FORCE MEMBERS, , Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B., ESC COMMITTEE FOR PRACTICE GUIDELINES, , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, A. J., Dean, V., Deckers, J. W., Despres, C., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J. L., Zamorano, J. L. (2006). ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114: e257-e354 [Full Text]
Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., Olsson, S. B., Prystowsky, E. N., Tamargo, J. L., Wann, S., ACC/AHA TASK FORCE MEMBERS, , Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B., ESC COMMITTEE FOR PRACTICE GUIDELINES, , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, A. J., Dean, V., Deckers, J. W., Despres, C., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J. L., Zamorano, J. L. (2006). ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114: 700-752 [Full Text]
Authors/Task Force Members, , Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., Olsson, S. B., Prystowsky, E. N., Tamargo, J. L., Wann, S., ESC Committee for Practice Guidelines, , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, A. J., Dean, V., Deckers, J. W., Despres, C., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J. L., Zamorano, J. L., ACC/AHA (Practice Guidelines) Task Force Members, , Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2006). ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur Heart J 27: 1979-2030 [Full Text]
Friberg, L., Hammar, N., Ringh, M., Pettersson, H., Rosenqvist, M. (2006). Stroke prophylaxis in atrial fibrillation: who gets it and who does not?: Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study). Eur Heart J 27: 1954-1964 [Abstract] [Full Text]
Cooper, N. J., Sutton, A. J., Lu, G., Khunti, K. (2006). Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation.. Arch Intern Med 166: 1269-1275 [Abstract] [Full Text]
Domanski, M. (2006). Prognosis in atrial fibrillation. Eur Heart J 27: 895-896 [Full Text]
Hylek, E. M., D'Antonio, J., Evans-Molina, C., Shea, C., Henault, L. E., Regan, S. (2006). Translating the Results of Randomized Trials into Clinical Practice: The Challenge of Warfarin Candidacy Among Hospitalized Elderly Patients With Atrial Fibrillation. Stroke 37: 1075-1080 [Abstract] [Full Text]
Currie, C J, Jones, M, Goodfellow, J, McEwan, P, Morgan, C L, Emmas, C, Peters, J R (2006). Evaluation of survival and ischaemic and thromboembolic event rates in patients with non-valvar atrial fibrillation in the general population when treated and untreated with warfarin. Heart 92: 196-200 [Abstract] [Full Text]
Fox, C. S., Larson, M. G., Vasan, R. S., Guo, C.-Y., Parise, H., Levy, D., Leip, E. P., O'Donnell, C. J., D'Agostino, R. B. Sr., Benjamin, E. J. (2006). Cross-Sectional Association of Kidney Function with Valvular and Annular Calcification: The Framingham Heart Study. J. Am. Soc. Nephrol. 17: 521-527 [Abstract] [Full Text]
Min, K. A., Zhu, X., Oh, J. M., Shin, W. G. (2006). Effect of oxolamine on anticoagulant effect of warfarin. Am J Health Syst Pharm 63: 153-156 [Full Text]
Roberts, R. (2006). Genomics and Cardiac Arrhythmias. J Am Coll Cardiol 47: 9-21 [Abstract] [Full Text]
Kaul, S., Diamond, G. A., Weintraub, W. S. (2005). Trials and Tribulations of Non-Inferiority: The Ximelagatran Experience. J Am Coll Cardiol 46: 1986-1995 [Abstract] [Full Text]
(2005). Additional Information. JAMA 294: E1-E3 [Full Text]
Waldo, A. L., Becker, R. C., Tapson, V. F., Colgan, K. J., for the NABOR Steering Committee, (2005). Hospitalized Patients With Atrial Fibrillation and a High Risk of Stroke Are Not Being Provided With Adequate Anticoagulation. J Am Coll Cardiol 46: 1729-1736 [Abstract] [Full Text]
Miyasaka, Y., Barnes, M. E., Gersh, B. J., Cha, S. S., Seward, J. B., Bailey, K. R., Iwasaka, T., Tsang, T. S.M. (2005). Time Trends of Ischemic Stroke Incidence and Mortality in Patients Diagnosed With First Atrial Fibrillation in 1980 to 2000: Report of a Community-Based Study. Stroke 36: 2362-2366 [Abstract] [Full Text]
Man-Son-Hing, M., Gage, B. F., Montgomery, A. A., Howitt, A., Thomson, R., Devereaux, P. J., Protheroe, J., Fahey, T., Armstrong, D., Laupacis, A. (2005). Preference-Based Antithrombotic Therapy in Atrial Fibrillation: Implications for Clinical Decision Making. Med Decis Making 25: 548-559 [Abstract]
Tapson, V. F., Hyers, T. M., Waldo, A. L., Ballard, D. J., Becker, R. C., Caprini, J. A., Khetan, R., Wittkowsky, A. K., Colgan, K. J., Shillington, A. C., for the NABOR (National Anticoagulation Benchmark, (2005). Antithrombotic Therapy Practices in US Hospitals in an Era of Practice Guidelines. Arch Intern Med 165: 1458-1464 [Abstract] [Full Text]
Olshansky, B., Heller, E. N., Mitchell, L. B., Chandler, M., Slater, W., Green, M., Brodsky, M., Barrell, P., Greene, H. L., and the AFFIRM Investigators, (2005). Are Transthoracic Echocardiographic Parameters Associated With Atrial Fibrillation Recurrence or Stroke?: Results From the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. J Am Coll Cardiol 45: 2026-2033 [Abstract] [Full Text]
Falk, R. H. (2005). Rate Control Is Preferable to Rhythm Control in the Majority of Patients With Atrial Fibrillation. Circulation 111: 3141-3150 [Full Text]
Katira, R, Chauhan, A, More, R S (2005). Direct thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillation. Postgrad. Med. J. 81: 370-375 [Abstract] [Full Text]
Sherman, D. G., Kim, S. G., Boop, B. S., Corley, S. D., DiMarco, J. P., Hart, R. G., Haywood, L. J., Hoyte, K., Kaufman, E. S., Kim, M. H., Nasco, E., Waldo, A. L., for the National Heart, Lung, and Blood Institute, (2005). Occurrence and Characteristics of Stroke Events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) Study. Arch Intern Med 165: 1185-1191 [Abstract] [Full Text]
Bath, P. M.W., Zhao, L., Heptinstall, S. (2005). Current status of stroke prevention in patients with atrial fibrillation. Eur Heart J Suppl 7: C12-C18 [Abstract] [Full Text]
Emmerich, J., Le Heuzey, J.-Y., Bath, P. M.W., Connolly, S. J. (2005). Indication for antithrombotic therapy for atrial fibrillation: reconciling the guidelines with clinical practice. Eur Heart J Suppl 7: C28-C33 [Abstract] [Full Text]
Miller, P. S.J., Drummond, M. F., Langkilde, L. K., McMurray, J. J.V., Ogren, M. (2005). Economic factors associated with antithrombotic treatments for stroke prevention in patients with atrial fibrillation. Eur Heart J Suppl 7: C41-C54 [Abstract] [Full Text]
O'Brien, C. L., Gage, B. F. (2005). Costs and Effectiveness of Ximelagatran for Stroke Prophylaxis in Chronic Atrial Fibrillation. JAMA 293: 699-706 [Abstract] [Full Text]
Page, R. L. (2004). Newly Diagnosed Atrial Fibrillation. NEJM 351: 2408-2416 [Full Text]
Reynolds, M. W., Fahrbach, K., Hauch, O., Wygant, G., Estok, R., Cella, C., Nalysnyk, L. (2004). Warfarin Anticoagulation and Outcomes in Patients With Atrial Fibrillation: A Systematic Review and Metaanalysis. Chest 126: 1938-1945 [Abstract] [Full Text]
Yousef, Z R, Tandy, S C, Tudor, V, Jishi, F, Trent, R J, Watson, D K, Cowell, R P W (2004). Warfarin for non-rheumatic atrial fibrillation: five year experience in a district general hospital. Heart 90: 1259-1262 [Abstract] [Full Text]
Ansell, J., Hirsh, J., Poller, L., Bussey, H., Jacobson, A., Hylek, E. (2004). The Pharmacology and Management of the Vitamin K Antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 204S-233S [Abstract] [Full Text]
Patrono, C., Coller, B., FitzGerald, G. A., Hirsh, J., Roth, G. (2004). Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 234S-264S [Abstract] [Full Text]
Levine, M. N., Raskob, G., Beyth, R. J., Kearon, C., Schulman, S. (2004). Hemorrhagic Complications of Anticoagulant Treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 287S-310S [Abstract] [Full Text]
Singer, D. E., Albers, G. W., Dalen, J. E., Go, A. S., Halperin, J. L., Manning, W. J. (2004). Antithrombotic Therapy in Atrial Fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 429S-456S [Abstract] [Full Text]
Salem, D. N., Stein, P. D., Al-Ahmad, A., Bussey, H. I., Horstkotte, D., Miller, N., Pauker, S. G. (2004). Antithrombotic Therapy in Valvular Heart Disease--Native and Prosthetic: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 457S-482S [Abstract] [Full Text]
Martins, J L, Fox, K F, Wood, D A, Lefroy, D C, Collier, T J, Peters, N S (2004). Rapid access arrhythmia clinic for the diagnosis and management of new arrhythmias presenting in the community: a prospective, descriptive study. Heart 90: 877-881 [Abstract] [Full Text]
Crystal, E., Connolly, S. J (2004). Role of oral anticoagulation in management of atrial fibrillation. Heart 90: 813-817 [Full Text]
Ezekowitz, M. D., Falk, R. H. (2004). The Increasing Need for Anticoagulant Therapy to Prevent Stroke in Patients With Atrial Fibrillation. Mayo Clin Proc. 79: 904-913 [Abstract]
Elkind, M. S.V., Sacco, R. L. (2004). Direct Thrombin Inhibition: A Novel Approach to Stroke Prevention in Patients With Atrial Fibrillation. Stroke 35: 1519-1522 [Full Text]
Hanna, I. R., Kolm, P., Martin, R., Reisman, M., Gray, W., Block, P. C. (2004). Left atrial structure and function after percutaneous left atrial appendage transcatheter occlusion (PLAATO): Six-month echocardiographic follow-up. J Am Coll Cardiol 43: 1868-1872 [Abstract] [Full Text]
Rosand, J., Eckman, M. H., Knudsen, K. A., Singer, D. E., Greenberg, S. M. (2004). The Effect of Warfarin and Intensity of Anticoagulation on Outcome of Intracerebral Hemorrhage. Arch Intern Med 164: 880-884 [Abstract] [Full Text]
Vora, A., Karnad, D., Goyal, V., Naik, A., Gupta, A., Lokhandwala, Y., Kulkarni, H., Singh, B. N. (2004). Control of Heart Rate Versus Rhythm in Rheumatic Atrial Fibrillation: A Randomized Study. J CARDIOVASC PHARMACOL THER 9: 65-73 [Abstract]
Dowd, M. B. (2004). Anticoagulation in the Elderly. Journal of Pharmacy Practice 17: 94-102 [Abstract]
Olsson, S.B. (2004). New advances in stroke prevention in atrial fibrillation: ximelagatran and direct thrombin inhibition. Eur Heart J Suppl 6: B20-B24 [Abstract] [Full Text]
O'Donnell, M., Hirsh, J. (2004). Establishing an Optimal Therapeutic Range for Coumarins: Filling in the Gaps. Arch Intern Med 164: 588-590 [Full Text]
Kaufman, E. S., Waldo, A. L. (2004). The impact of asymptomatic atrial fibrillation. J Am Coll Cardiol 43: 53-54 [Full Text]
Snow, V., Weiss, K. B., LeFevre, M., McNamara, R., Bass, E., Green, L. A., Michl, K., Owens, D. K., Susman, J., Allen, D. I., Mottur-Pilson, C., the Joint AAFP/ACP Panel on Atrial Fibrillation, (2003). Management of Newly Detected Atrial Fibrillation: A Clinical Practice Guideline from the American Academy of Family Physicians and the American College of Physicians. ANN INTERN MED 139: 1009-1017 [Abstract] [Full Text]
McNamara, R. L., Tamariz, L. J., Segal, J. B., Bass, E. B. (2003). Management of Atrial Fibrillation: Review of the Evidence for the Role of Pharmacologic Therapy, Electrical Cardioversion, and Echocardiography. ANN INTERN MED 139: 1018-1033 [Abstract] [Full Text]
Kasliwal, R. R, Mukesh, S., Manohar, G., Aggarwal, N., Bhatia, A. (2003). Pharmacotherapy of Atrial Fibrillation. Asian Cardiovasc. Thorac. Ann. 11: 364-374 [Abstract] [Full Text]
Go, A. S., Hylek, E. M., Chang, Y., Phillips, K. A., Henault, L. E., Capra, A. M., Jensvold, N. G., Selby, J. V., Singer, D. E. (2003). Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation: How Well Do Randomized Trials Translate Into Clinical Practice?. JAMA 290: 2685-2692 [Abstract] [Full Text]
Villani, G.Q., Piepoli, M., Villani, P.E., Capucci, A. (2003). Anticoagulation in atrial fibrillation: what is certain and what is to come. Eur Heart J Suppl 5: H45-H50 [Abstract]
Wattigney, W. A., Mensah, G. A., Croft, J. B. (2003). Increasing Trends in Hospitalization for Atrial Fibrillation in the United States, 1985 Through 1999: Implications for Primary Prevention. Circulation 108: 711-716 [Abstract] [Full Text]
Johnston, J. A., Cluxton, R. J. Jr, Heaton, P. C., Guo, J. J., Moomaw, C. J., Eckman, M. H. (2003). Predictors of Warfarin Use Among Ohio Medicaid Patients With New-Onset Nonvalvular Atrial Fibrillation. Arch Intern Med 163: 1705-1710 [Abstract] [Full Text]
Petersen, P., Grind, M., Adler, J., SPORTIF II Investigators, (2003). Ximelagatran versus warfarin forstroke prevention in patientswith nonvalvular atrial fibrillation: SPORTIF ii: a dose-guiding, tolerability, and safety study. J Am Coll Cardiol 41: 1445-1451 [Abstract] [Full Text]
Hirsh, J., Fuster, V., Ansell, J., Halperin, J. L. (2003). American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol 41: 1633-1652 [Full Text]

Comments and questions? Please contact us.